Joaquim Ferreira, MD, PhD, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, discusses the problems over administration methods and dosage of antisense oligonucleotides (ASOs) that are currently in clinical trials. Despite positive results in the early stages of the clinical trials, Prof. Ferreira says to be prudent and start preparing follow-up trials to gather additional information. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).